Evelo Biosciences Inc expected to post a loss of 16 cents a share - Earnings Preview

Evelo Biosciences

08/05/2023 16:02

* Evelo Biosciences Inc  EVLO.OQ   EVLO.O  is expected
to show no
change in quarterly revenue when it reports  results on May 10
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Evelo Biosciences
Inc is
for a loss of 16 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $1.5​, above​ its last closing price of $0.14. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.27       -0.28      -0.21     Beat    23.9
 Sep. 30 2022  -0.35       -0.33      -0.28     Beat    16.4
 Jun. 30 2022  -0.44       -0.43      -0.40     Beat    7.7​
 Mar. 31 2022  -0.58       -0.58      -0.56     Beat    3.8
 ​​Dec.                    -0.61      -0.54     Beat    11.5
 31 2021                                                
 Sep. 30 2021  -0.55       -0.54      -0.63     Missed  -16.7​
 Jun. 30 2021  -0.53       -0.54      -0.53     Beat    2.2
 Mar. 31 2021  -0.51       -0.51      -0.55     Missed  -8.7
 This summary was machine generated May 8 at 15:02 GMT.  All
figures in US dollars  unless otherwise stated